Aclidinium Bromide + Placebo
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
COPD
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Trial Timeline
Oct 16, 2013 → Sep 21, 2017
NCT ID
NCT01966107About Aclidinium Bromide + Placebo
Aclidinium Bromide + Placebo is a approved stage product being developed by AstraZeneca for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT01966107. Target conditions include COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD.
What happened to similar drugs?
20 of 20 similar drugs in COPD were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02375724 | Approved | Completed |
| NCT02153489 | Approved | Completed |
| NCT01966107 | Approved | Completed |
| NCT01471171 | Phase 3 | Completed |
| NCT01045161 | Phase 3 | Completed |
| NCT00500318 | Phase 3 | Completed |
| NCT00358436 | Phase 3 | Completed |
| NCT00363896 | Phase 3 | Completed |
Competing Products
20 competing products in COPD